Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harwell, J. I.
Right arrow Articles by Brown, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harwell, J. I.
Right arrow Articles by Brown, R. B.
(Chest. 2000;117:530-541.)
© 2000 American College of Chest Physicians

The Drug-Resistant Pneumococcus*

Clinical Relevance, Therapy, and Prevention

Joseph I. Harwell, MD and Richard B. Brown, MD, FCCP

* From the Division of Infectious Diseases, Baystate Medical Center, Springfield, MA; and Tufts University School of Medicine, Boston, MA.

Correspondence to: Richard B. Brown, MD, FCCP, Division of Infectious Diseases, Baystate Medical Center, 759 Chestnut St, Springfield, MA 01199

Streptococcus pneumoniae has been known for > 100 years as the most important bacterial pathogen of the respiratory tract in adults and children. In recent years, the pneumococcus has begun to exhibit increasing resistance to antimicrobial agents. Because of the huge number of infections caused by this organism, the development of resistance has changed the approach to many infectious disease problems, particularly with regard to empiric antibiotic therapy and prophylaxis. In our review of the antibiotic-resistant pneumococcus, we review the microbiologic basis for resistance, risk factors for and clinical relevance of infection by a resistant organism, and infection control measures.

Key Words: meningitis • otitis media • pneumococcus • pneumonia • resistance




This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
L D Liebowitz, M Slabbert, and A Huisamen
National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents
J. Clin. Pathol., May 1, 2003; 56(5): 344 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. S. Niederman, L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton, G. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, et al.
Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention
Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1730 - 1754.
[Full Text] [PDF]

Home page
 ChestHome page
A. A. Karcic, F. A. Khan, R. B. Brown, and J. I. Harwell
Ciprofloxacin vs the Pneumococcus
Chest, October 1, 2000; 118(4): 1226 - 1227.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Chest Physicians.